• Fri news: Pfizer’s $1B Chinese commitment. RFK Jr. and pharma. Eisai dials back Leqembi forecast. US diabetes burden increase. JNJ gets Varipulse approval. See more on our front page

Can the damage that Coats inflicted ever be fixed?























October 31st..today’s the day this company need to wear the right costume to somehow convince the AdComm that this product is better than what they presented the last time they went for T1D.
 




the compound was touted as, at first, selective SGLT2, then it was dual acting SGLT2 and SGLT1, then good for cardio, then it went in search of approval. what's the patent life left? is it better than the competition,
or
is this another in the long list of hopeful, best in class, class leading....FAILURES